BioInvent International Logo

BioInvent International

ISIN: SE0015244520 | Ticker: BINV | LEI: 549300E7QRHEF2IJUY10
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About BioInvent International

Company Description

BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit.

Headcount

93

Headquarters

Ideongatan 1, 22362 Lund – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 02.01.2020 01.01.2021 02.01.2021 01.01.2022 02.01.2022 01.01.2023
Assets N/A N/A 802,640,000.00 N/A 1,447,311,000.00 N/A 1,712,214,000.00
Noncurrent Assets N/A N/A 29,596,000.00 N/A 331,292,000.00 N/A 628,152,000.00
Office Equipment N/A N/A 16,182,000.00 N/A 21,395,000.00 N/A 24,880,000.00
Intangible Assets Other Than Goodwill N/A N/A 0.00 N/A 0.00 N/A 0.00
Current Assets N/A N/A 773,044,000.00 N/A 1,116,019,000.00 N/A 1,084,062,000.00
Inventories N/A N/A 4,079,000.00 N/A 16,848,000.00 N/A 11,506,000.00
Current Trade Receivables N/A N/A 29,920,000.00 N/A 370,000.00 N/A 15,780,000.00
Current Prepayments And Current Accrued Income Other Than Current Contract Assets N/A N/A N/A N/A 6,948,000.00 N/A 18,498,000.00
Cash and cash equivalents N/A 153,975,000.00 729,270,000.00 729,270,000.00 910,755,000.00 910,755,000.00 515,047,000.00
Equity And Liabilities N/A N/A 802,640,000.00 N/A 1,447,311,000.00 N/A 1,712,214,000.00
Equity 169,436,000.00 N/A 743,499,000.00 N/A 1,366,987,000.00 N/A 1,606,122,000.00
Issued Capital N/A N/A 78,752,000.00 N/A 11,694,000.00 N/A 12,994,000.00
Retained Earnings N/A N/A -1,817,317,000.00 N/A -2,094,623,000.00 N/A -2,135,337,000.00
Additional Paidin Capital N/A N/A 2,482,063,000.00 N/A 3,449,915,000.00 N/A 3,728,464,000.00
Equity Attributable To Owners Of Parent N/A N/A 743,499,000.00 N/A 1,366,987,000.00 N/A 1,606,122,000.00
Noncurrent Liabilities N/A N/A 5,632,000.00 N/A 21,532,000.00 N/A 18,773,000.00
Current Liabilities N/A N/A 53,509,000.00 N/A 58,792,000.00 N/A 87,319,000.00
Trade And Other Current Payables To Trade Suppliers N/A N/A 16,913,000.00 N/A 19,720,000.00 N/A 41,346,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A N/A N/A 23,201,000.00 N/A 31,972,000.00
Other Current Payables N/A N/A 8,016,000.00 N/A 9,036,000.00 N/A 5,811,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 147,372,000.00 19,384,000.00 326,126,000.00
Profit Loss From Operating Activities -75,474,000.00 -278,350,000.00 -50,921,000.00
Finance Income 625,000.00 623,000.00 9,212,000.00
Finance Costs 1,484,000.00 717,000.00 794,000.00
Profit Loss Before Tax -76,333,000.00 -278,444,000.00 -42,503,000.00
Income Tax Expense Continuing Operations 0.00 0.00 N/A
Profit (loss) -76,333,000.00 -278,444,000.00 -42,503,000.00
Line item in (sek) 01.01.2021 02.01.2020 01.01.2022 02.01.2021 01.01.2023 02.01.2022
Profit (loss) -76,333,000.00 N/A -278,444,000.00 N/A -42,503,000.00 N/A
Adjustments For Decrease Increase In Inventories 1,301,000.00 N/A -12,769,000.00 N/A 5,342,000.00 N/A
Adjustments For Depreciation And Amortisation Expense 12,004,000.00 N/A 14,610,000.00 N/A 14,724,000.00 N/A
Other Adjustments For Noncash Items -41,000.00 N/A 1,138,000.00 N/A 1,789,000.00 N/A
Interest Paid Classified As Operating Activities 335,000.00 N/A 517,000.00 N/A 650,000.00 N/A
Interest Received Classified As Operating Activities 28,000.00 N/A 248,000.00 N/A 606,000.00 N/A
Cash Flows From Used In Operating Activities -62,622,000.00 N/A -245,843,000.00 N/A -41,227,000.00 N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities 6,700,000.00 N/A 13,260,000.00 N/A 12,377,000.00 N/A
Cash Flows From Used In Investing Activities -6,700,000.00 N/A -467,542,000.00 N/A -628,848,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities 5,820,000.00 N/A 5,924,000.00 N/A 6,362,000.00 N/A
Cash Flows From Used In Financing Activities 644,617,000.00 N/A 894,870,000.00 N/A 273,487,000.00 N/A
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes 575,295,000.00 N/A 181,485,000.00 N/A -396,588,000.00 N/A
Cash and cash equivalents 729,270,000.00 153,975,000.00 910,755,000.00 729,270,000.00 515,047,000.00 910,755,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
09.01.24 Erik Esveld Other Buy SEK 70,960.00
30.06.23 Sylvie Ryckebusch Other Buy EUR 7,890.00
16.11.22 Dharminder Chahal Other Buy SEK 352,500.00
09.03.22 Martin Welschof Other Buy SEK 109,798.92
09.03.22 Martin Welschof Other Buy SEK 27,200.00
09.03.22 Martin Welschof Other Buy SEK 25,425.00
09.03.22 Martin Welschof Other Buy SEK 20,700.68
09.03.22 Martin Welschof Other Buy SEK 17,193.20
09.03.22 Martin Welschof Other Buy SEK 16,800.00
09.03.22 Martin Welschof Other Buy SEK 13,712.00

Capital markets information

ISIN

SE0015244520

LEI

549300E7QRHEF2IJUY10

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.